StreetAlpha
Cardiff Oncology, Inc. · Earnings

CRDF Earnings Results and History

Latest: Q3 2026From SEC 8-K, 10-Q and 10-K filings

Cardiff Oncology, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.

← CRDF stock page

Q3 2026 result
Beat on EPS
  • EPS−$0.12 vs −$0.14 est +13.0%
  • Revenue$171K +42.5% vs a year ago

Filed ยท Press release

Revenue growth+42.5%vs −27.3% a year ago
Operating margin−5391.2%vs −9978.3% a year ago

Key takeaways

from the press release
  • Q3 royalty revenue was $171 thousand, up from $120 thousand a year earlier. The company has no product sales.
  • Q3 net loss narrowed to $8.9 million from $11.3 million, as R&D spending fell sharply on completed trials and fewer patients.
3 more takeaways with a free account.Create free account

EPS by quarter

GAAP diluted, 12 quarters
Dec 2023: EPS -$0.21-0.21Dec '23Mar 2024: EPS -$0.22-0.22Mar '24Jun 2024: EPS -$0.26-0.26Jun '24Sep 2024: EPS -$0.25-0.25Sep '24Dec 2024: EPS -$0.21-0.21Dec '24Mar 2025: EPS -$0.20-0.20Mar '25Jun 2025: EPS -$0.21-0.21Jun '25Sep 2025: EPS -$0.17-0.17Sep '25Dec 2025: EPS -$0.11-0.11Dec '25Mar 2026: EPS -$0.18-0.18Mar '26Jun 2026: EPS -$0.14-0.14Jun '26Sep 2026: EPS -$0.12-0.12Sep '26

Revenue and operating margin

from 10-Q and 10-K
Dec 2023: revenue $156K-6623%Dec '23Mar 2024: revenue $205K-5333%Mar '24Jun 2024: revenue $163K-7696%Jun '24Sep 2024: revenue $165K-7637%Sep '24Dec 2024: revenue $151K-8326%Dec '24Mar 2025: revenue $109K-13194%Mar '25Jun 2025: revenue $121K-12212%Jun '25Sep 2025: revenue $120K-9978%Sep '25Dec 2025: revenue $243K-3221%Dec '25Mar 2026: revenue $41K-31341%Mar '26Jun 2026: revenue $104K-9245%Jun '26Sep 2026: revenue $171K-5391%Sep '26
RevenueOperating margin %

Quarter by quarter

from 10-Q and 10-K filings
Quarter endedRevenueGrowthOp marginNet incomeEPSFree cash flow
Sep 2026$171K+42.5%−5391.2%−$8.9M−$0.12−$9.9M
Jun 2026$104K−14.0%−9245.2%−$9.2M−$0.14–
Mar 2026$41K−62.4%−31341.5%−$12.3M−$0.18–
Dec 2025$243K+60.9%−3221.0%−$7.2M−$0.11−$6M
Create a free account to see all 12 quarters, or sign in.

EPS here is GAAP diluted, as filed with the SEC. Estimates are usually based on adjusted EPS, so the two can differ. Growth compares with the same quarter a year earlier.

Year by year

fiscal years, from 10-K filings
Year endedRevenueGrowthOp marginNet incomeEPS
Dec 31, 2025$593K−13.2%−8256.3%−$45.9M−$0.69
Dec 31, 2024$683K+40.0%−7123.1%−$45.4M−$0.95
Dec 31, 2023$488K+26.4%−9305.7%−$41.4M−$0.93
Dec 31, 2022$386K+7.5%−10337.3%−$38.7M−$0.89
Dec 31, 2021$359K–−8037.6%−$28.3M−$0.73

Filings and dates

SEC EDGAR

Also see CRDF institutional ownership and the earnings calendar.

CRDF earnings FAQ

What were CRDF's latest earnings?

For Q3 2026 Cardiff Oncology, Inc. reported revenue of $171K, GAAP EPS of -$0.12. The results were filed with the SEC on Nov 12, 2026.

When is CRDF's next earnings date?

There is no confirmed date on our calendar yet. Most companies report about four to six weeks after each quarter ends.

Is CRDF's revenue growing?

In the quarter ended Sep 30, 2026 revenue was $171K, up 42.5% from a year earlier. The table on this page shows every quarter from the company's 10-Q and 10-K filings.

Where do these numbers come from?

Results, guidance and financials come from Cardiff Oncology, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.